Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/16457
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVervaeck, A.-
dc.contributor.authorSaerens, L.-
dc.contributor.authorDe Geest, B. G.-
dc.contributor.authorDe Beer, T.-
dc.contributor.authorCARLEER, Robert-
dc.contributor.authorADRIAENSENS, Peter-
dc.contributor.authorRemon, J. P.-
dc.contributor.authorVervaet, C.-
dc.date.accessioned2014-03-20T11:52:48Z-
dc.date.available2014-03-20T11:52:48Z-
dc.date.issued2013-
dc.identifier.citationEUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 85 (3), p. 587-596-
dc.identifier.issn0939-6411-
dc.identifier.urihttp://hdl.handle.net/1942/16457-
dc.description.abstractIn this study, prilling was evaluated as a technique for the development of multiparticulate dosage forms using the fatty acids, stearic acid, and behenic acid as potential matrix formers to control the release of metoprolol tartrate (MPT), a highly water soluble drug. The in vitro drug release was dependent on the drug load, type of fatty acid, and pH of the dissolution medium. Higher drug loads resulted in faster release with behenic acid releasing drug over longer periods relative to stearic acid. The in vitro drug release was pH-dependent at low drug load with the release being slower at lower pH. Due to ionization of the fatty acid at pH 7.4, drug release was susceptible to the ionic strength at this pH value. Solid state characterization indicated that the crystalline state of the fatty acids was not affected by thermal processing via prilling, while the crystallinity of MPT was decreased. During storage, the amorphous MPT fraction recrystallized in the entire matrix. Drug release from behenic acid matrices was increased during storage at 40 C; however, no polymorphism of behenic acid was detected. The bioavailability of MPT, after oral administration to dogs as prills containing 30% and 40% MPT using behenic acid as matrix former, was not significantly different from a commercial sustained release reference formulation, although the 40% MPT prills showed a burst release.-
dc.language.isoen-
dc.rights© 2013 Elsevier B.V. All rights reserved.-
dc.subject.otherprilling; fatty acids; metoprolol tartrate; controlled release; multiparticulate dosage forms; stability-
dc.titlePrilling of fatty acids as a continuous process for the development of controlled release multiparticulate dosage forms-
dc.typeJournal Contribution-
dc.identifier.epage596-
dc.identifier.issue3-
dc.identifier.spage587-
dc.identifier.volume85-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.ejpb.2013.02.003-
dc.identifier.isi000330200400031-
item.fullcitationVervaeck, A.; Saerens, L.; De Geest, B. G.; De Beer, T.; CARLEER, Robert; ADRIAENSENS, Peter; Remon, J. P. & Vervaet, C. (2013) Prilling of fatty acids as a continuous process for the development of controlled release multiparticulate dosage forms. In: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 85 (3), p. 587-596.-
item.validationecoom 2015-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
item.contributorVervaeck, A.-
item.contributorSaerens, L.-
item.contributorDe Geest, B. G.-
item.contributorDe Beer, T.-
item.contributorCARLEER, Robert-
item.contributorADRIAENSENS, Peter-
item.contributorRemon, J. P.-
item.contributorVervaet, C.-
crisitem.journal.issn0939-6411-
crisitem.journal.eissn1873-3441-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
vervaeck 1.pdf
  Restricted Access
Published version2.44 MBAdobe PDFView/Open    Request a copy
Show simple item record

SCOPUSTM   
Citations

22
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

24
checked on May 16, 2024

Page view(s)

94
checked on Aug 8, 2022

Download(s)

86
checked on Aug 8, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.